Publicaciones en colaboración con investigadores/as de Grenoble Alpes University (24)

2024

  1. High prevalence of venous thrombotic events in Cushing’s syndrome: data from ERCUSYN and details in relation to surgery

    European Journal of Endocrinology, Vol. 190, Núm. 1, pp. 75-85

2023

  1. A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)

    The European respiratory journal, Vol. 61, Núm. 2

  2. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a clinical consensus statement of the ESC working group on pulmonary circulation and right ventricular function

    European heart journal, Vol. 44, Núm. 29, pp. 2659-2671

  3. Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG

    Critical Care, Vol. 27, Núm. 1

  4. Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia—a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

    Bone Marrow Transplantation, Vol. 58, Núm. 8, pp. 907-915

2022

  1. Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia

    Bone Marrow Transplantation, Vol. 57, Núm. 11, pp. 1657-1663

  2. Correction: Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia (Bone Marrow Transplantation, (2022), 57, 11, (1657-1663), 10.1038/s41409-022-01781-9)

    Bone Marrow Transplantation

  3. Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT

    Bone Marrow Transplantation, Vol. 57, Núm. 4, pp. 562-571

  4. Precision Glycodendrimers for DC-SIGN Targeting**

    European Journal of Organic Chemistry, Vol. 2022, Núm. 29

2021

  1. A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: The NeuroCOVID-19 Task Force of the European Academy of Neurology

    European Journal of Neurology, Vol. 28, Núm. 11, pp. 3849-3855

  2. DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist

    PLoS Pathogens, Vol. 17, Núm. 5

  3. EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic

    European Journal of Neurology, Vol. 28, Núm. 1, pp. 7-14

  4. Low-Valent Calix[4]arene Glycoconjugates Based on Hydroxamic Acid Bearing Linkers as Potent Inhibitors in a Model of Ebola Virus Cis-Infection and HCMV-gB-Recombinant Glycoprotein Interaction with MDDC Cells by Blocking DC-SIGN

    Journal of Medicinal Chemistry, Vol. 64, Núm. 19, pp. 14332-14343

  5. Primary prevention of COVID-19: Advocacy for vaccination from a neurological perspective

    European Journal of Neurology

  6. The European Academy of Neurology COVID-19 registry (ENERGY): an international instrument for surveillance of neurological complications in patients with COVID-19

    European Journal of Neurology, Vol. 28, Núm. 10, pp. 3303-3323

  7. Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 2, pp. 481-491

2020

  1. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)

    European Urology

  2. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees

    European Urology, Vol. 77, Núm. 2, pp. 223-250

  3. The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection

    European Journal of Neurology, Vol. 27, Núm. 9, pp. 1727-1737

2019

  1. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2109-2119